Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis

Abstract Venetoclax (VEN) combined with azacitidine (AZA) or decitabine (DEC) has been approved for older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy based on the pivotal VIALE-A trial. However, this trial only compared AZA + VEN with AZA monotherapy. Therefore, we comp...

Full description

Bibliographic Details
Main Authors:	Daehun Kwag, Byung-Sik Cho, Su-Yeon Bang, Jong Hyuk Lee, Gi-June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Hee-Je Kim
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-12-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00770-x

Similar Items

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
by: Su-Yeon Bang, et al.
Published: (2023-03-01)

Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis
by: Jae-Ho Yoon, et al.
Published: (2023-03-01)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
by: Ian M. Bouligny, et al.
Published: (2023-05-01)

Haploidentical versus Double-Cord Blood Stem Cells as a Second Transplantation for Relapsed Acute Myeloid Leukemia
by: Jong-Hyuk Lee, et al.
Published: (2023-01-01)

Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML
by: Gi-June Min, et al.
Published: (2023-11-01)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
by: Kateryna Fedorov, et al.
Published: (2023-08-01)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
by: Gi-June Min, et al.
Published: (2023-10-01)

IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine
by: Poorva Vaidya, et al.
Published: (2024-01-01)

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
by: Mihee Kim, et al.
Published: (2023-07-01)

Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification
by: Tong-Yoon Kim, et al.
Published: (2022-06-01)

Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
by: Tong-Yoon Kim, et al.
Published: (2022-09-01)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
by: Denise Maravalle, et al.
Published: (2022-05-01)

LC–MS/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE: Application to pharmacokinetic study
by: Abdulaziz I. Alnasser, et al.
Published: (2023-09-01)

Long-term treatment outcome of Castleman’s disease: A real-world experience
by: Gi-June Min, et al.
Published: (2022-08-01)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
by: Seungyoun Kim, et al.
Published: (2021-12-01)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
by: Patrick J. Stiff, et al.
Published: (2023-09-01)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
by: Young‐Woo Jeon, et al.
Published: (2019-11-01)

Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine
by: Mihee Kim, et al.
Published: (2024-12-01)

A Novel Cognition of Decitabine: Insights into Immunomodulation and Antiviral Effects
by: Ji Xiao, et al.
Published: (2022-03-01)

Therapeutic effect of folic acid combined with decitabine on diabetic mice
by: Gang Du, et al.
Published: (2023-11-01)

Molecular predictors for decitabine efficacy in meningiomas – a pilot study.
by: Dorothee Spille, et al.
Published: (2023-01-01)

Decitabine attenuates ischemic stroke by reducing astrocytes proliferation in rats.
by: Qi Zhang, et al.
Published: (2022-01-01)

Teratogenic effect of decitabine in a pregnant patient with acute myeloid leukemia: a case report
by: Bee Sun Lee, et al.
Published: (2022-07-01)

Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
by: Ruth Halaban, et al.
Published: (2009-01-01)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
by: John Paul Yun, et al.
Published: (2023-08-01)

Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism
by: Wade R. Gutierrez, et al.
Published: (2022-11-01)

Absence of early platelet increment in healthy mice during decitabine treatment
by: Juliane Baumann, et al.
Published: (2022-12-01)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
by: Alex Bataller, et al.
Published: (2023-08-01)

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY
by: M. Yilmaz, et al.
Published: (2022-06-01)

Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression
by: Janneke F. Linnekamp, et al.
Published: (2021-05-01)

PB1849: EARLY SALVAGE THERAPY WITH VENETOCLAX AND 10-DAY DECITABINE IS FEASIBLE AND SAFE IN REFRACTORY AML: RESULTS FROM 11 PATIENTS WITH EARLY INDUCTION FAILURE
by: Carla Borst, et al.
Published: (2023-08-01)

Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i>
by: Byung-Sik Cho, et al.
Published: (2021-01-01)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
by: Amer M. Zeidan, et al.
Published: (2023-08-01)

MITOTIC PERTURBATION IS A KEY MECHANISM OF ACTION OF DECITABINE IN MYELOID TUMOR TREATMENT
by: T. Yabushita, et al.
Published: (2024-01-01)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
by: Y. Saunthararajah, et al.
Published: (2023-04-01)

P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML
by: Jacobien Hilberink, et al.
Published: (2023-08-01)

P407: MITOTIC FIDELITY IS A RESISTANCE MECHANISM TO DECITABINE IN MYELOID TUMORS.
by: Tomohiro Yabushita, et al.
Published: (2023-08-01)

The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine
by: Alicja Pawlak, et al.
Published: (2022-03-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
by: Hongjiao Li, et al.
Published: (2023-09-01)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
by: Robert Briski, et al.
Published: (2023-10-01)